Cohort1: Vulvar SCC
|
Administration route |
infusion |
Dosage |
0.01~1.2E11 cells |
Donor type |
autologous |
Pts |
1 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
Outcome |
1/1(PR) |
Adverse reactions |
no TCR related AEs |
References |
PMID:
33558725
|
|
Cohort2: Head and Neck SCC
|
Administration route |
infusion |
Dosage |
0.01~1.2E11 cells |
Donor type |
autologous |
Pts |
4 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
Outcome |
1/4(PR); 2/4(SD) |
Adverse reactions |
no TCR related AEs |
References |
PMID:
33558725
|
|
Cohort3: Cervical SCC
|
Administration route |
infusion |
Dosage |
0.01~1.2E11 cells |
Donor type |
autologous |
Pts |
4 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
Outcome |
3/4(PR); 1/4(SD) |
Adverse reactions |
no TCR related AEs |
References |
PMID:
33558725
|
|
Cohort4: Cervical Adenocarcinoma
|
Administration route |
infusion |
Dosage |
0.01~1.2E11 cells |
Donor type |
autologous |
Pts |
1 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
Outcome |
1/1(SD) |
Adverse reactions |
no TCR related AEs |
References |
PMID:
33558725
|
|
Cohort5: Anal SCC
|
Administration route |
infusion |
Dosage |
0.01~1.2E11 cells |
Donor type |
autologous |
Pts |
2 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
Outcome |
1/2(PR) |
Adverse reactions |
no TCR related AEs |
References |
PMID:
33558725
|
|